JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB156590

Anti-CBR1 antibody [EPR9660]

Be the first to review this product! Submit a review

|

(2 Publications)

Rabbit Recombinant Monoclonal CBR1 antibody. Suitable for IHC-P, WB, ICC/IF and reacts with Human samples. Cited in 2 publications.

View Alternative Names

CBR, CRN, SDR21C1, CBR1, Carbonyl reductase [NADPH] 1, 15-hydroxyprostaglandin dehydrogenase [NADP(+)], 20-beta-hydroxysteroid dehydrogenase, Alcohol dehydrogenase [NAD(P)+] CBR1, NADPH-dependent carbonyl reductase 1, Prostaglandin 9-ketoreductase, Prostaglandin-E(2) 9-reductase, Short chain dehydrogenase/reductase family 21C member 1, PG-9-KR

7 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CBR1 antibody [EPR9660] (AB156590)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CBR1 antibody [EPR9660] (AB156590)

ab156590 showing +ve staining in Human thyroid gland carcinoma.

Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CBR1 antibody [EPR9660] (AB156590)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CBR1 antibody [EPR9660] (AB156590)

ab156590 showing +ve staining in Human skeletal muscle.

Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CBR1 antibody [EPR9660] (AB156590)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CBR1 antibody [EPR9660] (AB156590)

ab156590 showing +ve staining in Human gastric carcinoma.

Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CBR1 antibody [EPR9660] (AB156590)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CBR1 antibody [EPR9660] (AB156590)

Immunohistochemical analysis of paraffin-embedded Human kidney tissue labeling CBR1 with ab156590 at 1/50 dilution.

Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

Immunocytochemistry/ Immunofluorescence - Anti-CBR1 antibody [EPR9660] (AB156590)
  • ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-CBR1 antibody [EPR9660] (AB156590)

Immunofluorescent analysis of HeLa cells labeling CBR1 with ab156590 at 1/50 dilution.

Western blot - Anti-CBR1 antibody [EPR9660] (AB156590)
  • WB

Lab

Western blot - Anti-CBR1 antibody [EPR9660] (AB156590)

Lanes 1-3 : Merged signal (red and green). Green - ab156590 observed at 30 kDa. Red - loading control ab8245 observed at 36 kDa.

ab156590 Anti-CBR1 antibody [EPR9660] was shown to specifically react with CBR1 in wild-type A549 cells. Loss of signal was observed when knockout cell line ab266954 (knockout cell lysate ab257874) was used. Wild-type and CBR1 knockout samples were subjected to SDS-PAGE. ab156590 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-CBR1 antibody [EPR9660] (ab156590) at 1/1000 dilution

Lane 1:

Wild-type A549 cell lysate at 20 µg

Lane 2:

CBR1 knockout A549 cell lysate at 20 µg

Lane 2:

Western blot - Human CBR1 knockout A549 cell line (<a href='/en-us/products/cell-lines/human-cbr1-knockout-a549-cell-line-ab266954'>ab266954</a>)

Lane 3:

HeLa cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/10000 dilution

Predicted band size: 30 kDa

Observed band size: 30 kDa

false

Western blot - Anti-CBR1 antibody [EPR9660] (AB156590)
  • WB

Unknown

Western blot - Anti-CBR1 antibody [EPR9660] (AB156590)

All lanes:

Western blot - Anti-CBR1 antibody [EPR9660] (ab156590) at 1/1000 dilution

Lane 1:

HeLa cell lysate at 10 µg

Lane 2:

293T cell lysate at 10 µg

Lane 3:

SH-SY5Y cell lysate at 10 µg

Lane 4:

Human fetal kidney lysate at 10 µg

Secondary

All lanes:

Goat anti-rabbit HRP at 1/2000 dilution

Predicted band size: 30 kDa

false

  • Carrier free

    Anti-CBR1 antibody [EPR9660] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR9660

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

WB, ICC/IF, IHC-P

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/50 - 1/100", "IHCP-species-notes": "<p></p>", "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "<p></p>", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/10000", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/50 - 1/100", "ICCIF-species-notes": "<p></p>" } } }

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Species reactivity
Rat: We have preliminary internal testing data to indicate this antibody may not react with this species.
Please contact us for more information.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Cbr1 also known as carbonyl reductase 1 is an important enzyme in the reduction of carbonyl compounds to their alcohol forms. It weighs around 30 kDa and exhibits a wide expression across various tissues but is notably present in the liver and heart. The enzyme acts as a monomer and follows an NADPH-dependent mechanism for its action playing an important role in the detoxification of xenobiotics and the metabolism of endogenous compounds.
Biological function summary

Carbonyl reductase 1 functions in the metabolism of prostaglandins steroids and aromatic aldehydes. Cbr1 is not known to form part of a larger protein complex but acts independently to execute its enzymatic roles. It exhibits broad substrate specificity allowing it to reduce a variety of carbonyl groups which influences several physiological processes such as lipid metabolism and hormone synthesis.

Pathways

The enzyme plays an important role in the prostaglandin metabolic pathway where it reduces prostaglandin E2. Additionally Cbr1 interacts within the retinol metabolism pathway. In these pathways it functions alongside proteins such as aldo-keto reductases and aldose reductase sharing substrate specificity which impacts cellular responses and metabolic regulation.

Cbr1 influences the development of drug resistance in cancer therapy particularly in anthracycline-treated cancers due to its role in drug metabolism. It also associates with cardiovascular conditions where its metabolic activity might affect oxidative stress levels. Connections with other proteins such as superoxide dismutases link Cbr1 to oxidative stress response pathways impacting disease progression and therapy outcomes.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol (PubMed : 15799708, PubMed : 17344335, PubMed : 17912391, PubMed : 18449627, PubMed : 18826943, PubMed : 1921984, PubMed : 7005231). Can convert prostaglandin E to prostaglandin F2-alpha (By similarity). Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione (PubMed : 17344335, PubMed : 18826943). In addition, participates in the glucocorticoid metabolism by catalyzing the NADPH-dependent cortisol/corticosterone into 20beta-dihydrocortisol (20b-DHF) or 20beta-corticosterone (20b-DHB), which are weak agonists of NR3C1 and NR3C2 in adipose tissue (PubMed : 28878267).
See full target information CBR1

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

Molecules and cells 42:672-685 PubMed31486328

2019

Upregulation of Carbonyl Reductase 1 by Nrf2 as a Potential Therapeutic Intervention for Ischemia/ Reperfusion Injury during Liver Transplantation.

Applications

Unspecified application

Species

Unspecified reactive species

Jae Hyun Kwon,Jooyoung Lee,Jiye Kim,Varvara A Kirchner,Yong Hwa Jo,Takeshi Miura,Nayoung Kim,Gi-Won Song,Shin Hwang,Sung-Gyu Lee,Young-In Yoon,Eunyoung Tak

Molecular and clinical oncology 8:400-406 PubMed29456845

2018

Low carbonyl reductase 1 expression is associated with poor prognosis in patients with oral squamous cell carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Ryota Yamanouchi,Koji Harada,Tarannum Ferdous,Yoshiya Ueyama
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com